Resources Repository
-
ReviewPublication 2016Dynamic Transmission Economic Evaluation of Infectious Disease in LMIC
Economic evaluation using dynamic transmission models is important for capturing the indirect effects of infectious …
Economic evaluation using dynamic transmission models is important for capturing the indirect effects of infectious disease interventions. The authors examine the use of these methods in low- and middle-income countries, where infectious diseases constitute a major burden. The review is comprised of two parts: (1) a summary of dynamic transmission economic evaluations across all disease areas published between 2011 and mid-2014 and (2) an in-depth review of mosquito-borne disease studies focusing on health economic methods…
Asia & Pacific | Middle East & North Africa | Infectious Diseases | Dynamic Transmission | Cost-Effectiveness Analysis | Economics/Finance | Health/Medicine | Sub-Saharan Africa | Latin America & Caribbean -
ReviewPublication 2016Using Economic Evidence to Set Healthcare Priorities in LMIC
Policy makers in low-income and lower-middle-income countries (LMICs) are increasingly looking to develop ‘evidence-based’ frameworks …
Policy makers in low-income and lower-middle-income countries (LMICs) are increasingly looking to develop ‘evidence-based’ frameworks for identifying priority health interventions. This paper synthesizes and appraises the literature on methodological frameworks – which incorporate economic evaluation evidence – for the purpose of setting healthcare priorities in LMICs. A systematic search of Embase, MEDLINE, Econlit and PubMed identified 3968 articles with a further 21 articles identified through manual searching. A total of 36 papers were eligible for inclusion.…
Asia & Pacific | Middle East & North Africa | Policy/Regulation | Priority Setting/Ethics | Benefit-Cost Analysis | Cost-Effectiveness Analysis | Technology Assessment | Health Systems | Economics/Finance | Government/Law | Health/Medicine | Sub-Saharan Africa | Latin America & Caribbean -
ReviewPublication 2015Medicare's Use of CEA for Prevention (But Not Treatment)
Medicare currently pays for 23 preventive services in its benefits package, the majority of which …
Medicare currently pays for 23 preventive services in its benefits package, the majority of which were added since 2005. In the past decade, the program has transformed from one essentially administering treatment claims, to one increasingly focused on health promotion and maintenance. What is largely unappreciated is the role cost-effectiveness analysis has played in the coverage of preventive services. This study reviews the role of cost-effectiveness analysis in Medicare coverage of preventive services and contrast it…
North America | Policy/Regulation | Infectious Diseases | Priority Setting/Ethics | Cost-Effectiveness Analysis | Technology Assessment | Child/Nutrition | Chronic Disease/Risk | Health Systems | Economics/Finance | Government/Law | Health/Medicine -
ReviewPublication 2003Public Health Policy and Cost-Effectiveness Analysis
This chapter presents an overview of the uses for cost-effectiveness analysis and disease-simulation modeling to …
This chapter presents an overview of the uses for cost-effectiveness analysis and disease-simulation modeling to rigorously evaluate alternatives to reduce mortality from cervical cancer. Scientific advances have provided opportunities over time to revisit strategies for cervical cancer prevention. How to invest health resources wisely, such that public health benefits are maximized-and opportunity costs are minimized-is a critical question in the setting of enhanced cytologic screening methods, human papillomavirus DNA testing, and vaccine development. Developing sound…
Global | Policy/Regulation | Infectious Diseases | Mathematical Models | Cost-Effectiveness Analysis | Chronic Disease/Risk | Health Systems | Health/Medicine -
ReviewPublication 2021Considerations for Diagnostic COVID-19 Tests
During the initial stages of the COVID-19 pandemic, there was a rush by numerous diagnostic …
During the initial stages of the COVID-19 pandemic, there was a rush by numerous diagnostic test manufacturers to create, validate, and implement testing methods. This review discusses the pivotal role of diagnostic tests during the pandemic's first global wave, highlighting the challenges in technology and implementation experienced early on. The study also offers insights for enhancing the use of diagnostics, especially syndromic ones, should there be future spikes or regional outbreaks of COVID-19. The overarching…
North America | Infectious Diseases | Test Performance | Clinical Care | Health/Medicine | Science/Technology -
ReviewPublication 2022Rapid, Point-of-Care Antigen Tests for Diagnosis of SARS-CoV-2 Infection
This study reviewed the diagnostic accuracy of rapid, point-of-care antigen tests for detecting SARS-CoV-2 infection, …
This study reviewed the diagnostic accuracy of rapid, point-of-care antigen tests for detecting SARS-CoV-2 infection, differentiating results between symptomatic and asymptomatic individuals. Using data from 155 study cohorts, the study found that the sensitivity of antigen tests was generally higher for symptomatic individuals, especially during the first week after symptom onset, due to higher viral loads. For example, average sensitivity was higher in symptomatic (73.0%) compared to asymptomatic participants (54.7). Average sensitivity was higher in…
North America | Infectious Diseases | Test Performance | Clinical Care | Health/Medicine | Science/Technology -
ReviewPublication 2022Significance of Advanced COVID-19 Diagnostic Testing in Pandemic Control Measures
Over the past two years of the COVID-19 pandemic, the scientific community has mounted significant …
Over the past two years of the COVID-19 pandemic, the scientific community has mounted significant efforts to combat the highly transmissible SARS-CoV-2 virus. Despite substantial progress in vaccines and treatments, leading to lower hospitalization and death rates, the virus has continued to evolve, primarily through mutations. From the onset, diagnostic tests have been crucial in identifying and controlling the virus spread. The scientific world has pioneered various diagnostic techniques, including nucleic acid, antigen, and antibody-based…
North America | Infectious Diseases | Test Performance | Health Systems | Clinical Care | Health/Medicine | Science/Technology -
ReviewPublication 2023Handbook of Vaccine Health Economics
The open-access book, "Handbook of Applied Health Economics in Vaccines," looks at the complexities of …
The open-access book, "Handbook of Applied Health Economics in Vaccines," looks at the complexities of vaccine discovery, financing, and distribution. It highlights the inadequacy of standard economic models for vaccines. The book explores alternative principles challenging market-based approaches and equips readers with tools for assessing costs and benefits through practical exercises. It serves as a comprehensive resource for decision-making in vaccine development and distribution and emphasizes the importance of considering broader perspectives beyond economic efficiency.…
Global | Policy/Regulation | Costing Methods | Health Outcomes | Evidence Synthesis | Decision Analysis | Benefit-Cost Analysis | Cost-Effectiveness Analysis | Health/Medicine | Graduate | Doctoral | Professional -
ReviewPublication 2022Systematic Review of Economic Evaluations of COVID-19 Interventions: Non-Health Impacts and Distributional Issues
The authors conducted a systematic review of economic evaluations of COVID-19 interventions and assessed whether …
The authors conducted a systematic review of economic evaluations of COVID-19 interventions and assessed whether they incorporated non-health impacts and distributional concerns. Among the 70 articles included, more than half (56%) included at least one non-health impact, although only 21% incorporated non-economic consequences. Only 17% examined subgroups of interest. The median ICER for the entire sample was $67,000/quality-adjusted life-year (QALY) (interquartile range [IQR] $9000-$893,000/QALY). Interventions including a pharmaceutical component yielded a median ICER of $93,000/QALY (IQR…
North America | Infectious Diseases | Evidence Synthesis | Cost-Effectiveness Analysis | Social Determinants | Culture/Society | Economics/Finance | Health/Medicine